Introduction
D-Mannose is a naturally occurring sugar widely used in the dietary supplements industry for its beneficial properties, particularly in the prevention of urinary tract infections (UTIs). This monosaccharide is best known for its ability to prevent bacterial adhesion to the bladder wall, significantly reducing recurrent UTIs. However, the application of D-Mannose in nutraceutical formulations faces certain challenges, primarily related to its rapid intestinal transit and limited bioavailability, compromising its effectiveness and duration of action. These limitations lead formulators to use high-dose administrations, which often result in poor patient compliance.
.
Therapeutic Properties of D-Mannose
- Prevention of Urinary Tract Infections (UTIs):
D-Mannose acts through a mechanical mode of action by binding to pathogenic bacteria such as Escherichia coli, preventing their adhesion and facilitating their natural removal through urinary flow. Thismechanismdramaticallyreducesrecurrentepisodes of UTIs. - Immune Support and Anti-inflammatory Properties:
Emerging studies suggest D-Mannose may also exert beneficial effects on local immunity, helping reduce inflammation in the urinary tract and improving the body’s natural immune response. - Innovative Applications:
Recent research has explored innovative potential applications of D-Mannose in other therapeutic areas, including intestinal health, aiming to inhibit the proliferation of pathogenic bacteria and promote microbiota balance.
Formulation Challenges of D-Mannose
Despite its numerous benefits, D-Mannose encounters significant formulation challenges:
- Short Residence Time and Low Bioavailability:
The rapid elimination of D-Mannose may compromise the duration of antibacterial protection needed to effectively prevent recurrent UTIs. - Difficulty in Dosage:
Variability in absorption rates often complicates the formulation of products that ensure consistent and reproducible availability of the active ingredient, essential for stable clinical effectiveness.
IPS Innovation: D-Mannose MATRIS® RETARD GP
To address these needs, IPS developed D-Mannose MATRIS® RETARD GP utilizing patented MATRIS® technology. This innovative formulation provides extended, controlled release up to 8 hours, ensuring optimal and sustained bioavailability throughout the intestinal tract. Additionally, its incorporated gastro-protective coating preserves the active ingredient during gastric transit, significantly reducing premature dispersion and notably enhancing antibacterial effectiveness.
From now on, IPS offers a range of D-Mannose formulations with different release profiles, further simplifying the development of personalized, accurately dosed supplements for manufacturers.
Scientific Studies and Collaborations
The SURACTIVES® division of IPS collaborates with prestigious academic institutions and specialized laboratories conducting preclinical in vitro studies using advanced models such as organoids and 3D cellular systems. These studies, although conducted on active ingredients other than D-Mannose, have confirmed that patented MATRIS® technology significantly improves intestinal absorption and drastically reduces gastric and intestinal membrane irritation. Encouraged by these positive results, IPS is currently performing further specific studies on D-Mannose MATRIS® to scientifically confirm these benefits also in relation to this specific ingredient.
Formulations and Applications
The versatility of MATRIS® technology allows formulation into various dosage forms such as tablets, capsules, single-dose sachets, stick packs, and vials with dosing caps. Moreover, for direct compression applications, IPS offers SmarTTabs® formulations, ensuring retention of the original active release profile, critical for final product efficacy.
Conclusion
D-Mannose MATRIS® RETARD GP represents a significant advancement in the nutraceutical industry, providing an innovative technological solution effectively addressing the formulation challenges of D-Mannose. Through continuous research and dedication to innovation, IPS continues to set new quality standards, offering advanced, scientifically validated products to enhance consumer health and well-being.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
